We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 96

Teva Canada Innovation v. Attorney General of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 13 2013

In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The

Ontario Court dismisses generic claims for unjust enrichment in s. 8 proceeding

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 30 2013

Apotex sued Abbott and Takeda for damages pursuant to s. 8 of the NOC Regulations. As part of the claim, Apotex claimed disgorgement of profits

Court dismisses NOC proceeding for mootness when NOA withdrawn

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 30 2013

Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to

Judicial review brought outside time period and no vested right to NOC

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 23 2013

This decision relates to the consideration by the Minister of Health of Apotex’ submission for a Notice of Compliance (NOC) for omeprazole magnesium

Definition of “innovative drug” does not include variations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 23 2013

This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s

Impeachment action in respect of expired patent allowed to continue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 17 2012

Apotex commenced an impeachment action in respect of two patents. Warner-Lambert brought a motion seeking to dismiss the action as it related to one patent

Court of Appeal considers comity as it applies to NOC proceedings

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 4 2012

Apotex v

Motion to determine preliminary question of law dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 21 2012

Pfizer brought a motion to have the Court determine a question of law before or at the outset of the trial of the action